<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04607447</url>
  </required_header>
  <id_info>
    <org_study_id>KY2020-063</org_study_id>
    <nct_id>NCT04607447</nct_id>
  </id_info>
  <brief_title>Low Intracranial Pressure Treatment Strategies for Chronic Subdural Hematoma Patients</brief_title>
  <acronym>CSDH-LP</acronym>
  <official_title>Effectiveness and Safety of Low Intracranial Pressure Treatment Strategies for Patients With Chronic Subdural Hematoma - A Randomized, Controlled, Multi-center Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proportion of the elderly population is increasing rapidly. Chronic subdural hematoma has&#xD;
      become the most common cause of surgery in neurosurgery for elderly patients. The standard&#xD;
      treatment for cSDH is mostly surgery. Clinically, we often encounter elderly patients with&#xD;
      certain underlying diseases or organ dysfunction, especially preexisting cardiovascular&#xD;
      disease or medication history like anticoagulant or antiplatelet drugs, resulting in poor&#xD;
      surgical tolerance, high risk during anesthesia and hematoma recurrence. At present, the&#xD;
      mechanism of cSDH is not completely clear. Our previous observational studies had shown&#xD;
      significant correlation between cSDH and intracranial hypotension. So we would like to&#xD;
      conduct a randomized, controlled, multi-center clinical study to explore the effectiveness&#xD;
      and safety of low intracranial pressure treatment strategies for patients with chronic&#xD;
      subdural hematoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>subdural hematoma volume</measure>
    <time_frame>three months</time_frame>
    <description>difference of hematoma volume in subdura between two groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markwalder scale</measure>
    <time_frame>three months</time_frame>
    <description>difference of Markwalder scale between two groups;The Markwalder Scale is designed to measure the chronic subdural hematoma scale. This scale is categorized into four grade. Grade 0 denots the patient neurologically normal, whereas grade 4, the highest grade, denotes the worst neuological assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>three months</time_frame>
    <description>difference of Modified Rankin Scale between two groups; The modified Rankin Scale is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extended Glasgow Outcome score</measure>
    <time_frame>three months</time_frame>
    <description>difference of Extended Glasgow Outcome score between two groups; This score is used to measure the outcome after neurological disease. It defines 5 categories of possible outcomes after a brain injury, which is from good recovery(5) to death(1).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Chronic Subdural Hematoma</condition>
  <arm_group>
    <arm_group_label>Atorvastatin plus Dexamethasone tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>drugs+low intracranial pressure strategy treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drugs means treatment with Atorvastatin plus Dexamethasone tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>low intracranial pressure strategy treatment</intervention_name>
    <description>Supine position for 16h-18h daily, with head toward the affected side in most of the time, and 15-20 cm elevation of lower limbs.&#xD;
Abdominal belt compression</description>
    <arm_group_label>drugs+low intracranial pressure strategy treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin plus Dexamethasone</intervention_name>
    <description>Atorvastatin plus Dexamethasone</description>
    <arm_group_label>Atorvastatin plus Dexamethasone tablets</arm_group_label>
    <arm_group_label>drugs+low intracranial pressure strategy treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients above 14 yrs with chronic subdural hematoma confirmed by cranial imaging;&#xD;
&#xD;
          -  patients with MGS-GCS score ≤1 point, showing no signs of neurological deficits caused&#xD;
             by CSDH or characteristics of high intracranial pressure;&#xD;
&#xD;
          -  patients with MGS-GCS score ≥1 point, but with medication history of anticoagulant or&#xD;
             antiplatelet drugs, coagulation dysfunction so that they are unsuitable or intolerant&#xD;
             of surgery although they are in stable condition;&#xD;
&#xD;
          -  patients who are unwilling to operate when they have no life-threatening brain&#xD;
             herniation or no indications for emergency surgery, which confirmed by two&#xD;
             neurosurgeons&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women pregnant or in lactation&#xD;
&#xD;
          -  those who are allergic to atorvastatin, hypoxamethasone;&#xD;
&#xD;
          -  patients with brain herniation or altered mental status;&#xD;
&#xD;
          -  patients with primary diseases like tumors, hemorrhagic diseases or some other&#xD;
             critically serious conditions( eg.multiple organ failure);&#xD;
&#xD;
          -  patients with uncontrollable diabetes and heart failure&#xD;
&#xD;
          -  patients with preexisting chronic abdominal diseases (such as inflammatory bowel&#xD;
             disease) or lung tumors or digestive system neoplasm&#xD;
&#xD;
          -  Patients with abnormal liver function&#xD;
&#xD;
          -  patients had taken atorvastatin or dexamethasone, ACEI in the past one week&#xD;
&#xD;
          -  other conditions not eligible to enroll the trial confirmed by two individual doctor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xuehai wu, phD</last_name>
    <phone>8613764880571</phone>
    <email>wuxuehai2013@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xiangru Ye, Master</last_name>
    <phone>8618818210651</phone>
    <email>xiangruye@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xuehai wu, PhD</last_name>
      <phone>8613764880571</phone>
      <email>wuxuehai2013@163.com</email>
    </contact>
    <contact_backup>
      <last_name>xiangru ye, Master</last_name>
      <phone>8618818210651</phone>
      <email>xiangruye@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Xuehai Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Low intracranial pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
    <mesh_term>Intracranial Hypotension</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

